<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03600974</url>
  </required_header>
  <id_info>
    <org_study_id>xhnk002</org_study_id>
    <nct_id>NCT03600974</nct_id>
  </id_info>
  <brief_title>A New System for GERD Diagnosis and Treatment</brief_title>
  <acronym>EAISMLP</acronym>
  <official_title>A New System for Diagnosis and Treatment of Gastroesophageal Refulx Diseases : Based on Endoscopy, pH Parameter, Impedence Parameter, High Resolution Manometry and Psychology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Capital Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Capital Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study measuring a new diagnosis and treatment system &quot;EAISMLP&quot; in adult
      patients with gastroesophageal reflux disease (GERD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators created a new diagnosis and treatment system for gastroesophageal reflux
      disease (GERD). The system based on endoscopy, 24h esophageal pH-impedance monitoring,
      esophagus high resolution manometry and psycological condition.the investigators named it as
      &quot;EAISMLP&quot; symptom. Each letter in &quot;EAISMLP&quot; is responsible for a typical character and
      treatment. Subjects will be subtyped according to &quot;EAISMLP&quot; system and underwent treatment,
      and will be follow up for 6 months and 1 years.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2019</start_date>
  <completion_date type="Anticipated">July 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Satisfaction of the &quot;EAISMLP system&quot; on GERD symptoms assessed by the HRQL scores.</measure>
    <time_frame>Change from Baseline HRQL scores at 1 month;Change from Baseline HRQL scores at 2 months;Change from Baseline HRQL scores at 6 months;Change from Baseline HRQL scores at 1 year</time_frame>
    <description>mean improvement in the GERD-health-related quality of life (HRQL) scores. Scale ranges 0-50 points, the lower score means the better efficacy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Satisfaction of the &quot;EAISMLP system&quot; on life quality assessed by the SF-36 scores.</measure>
    <time_frame>Change from Baseline SF-36 scores at 1 month;Change from Baseline SF-36 scores at 2 months;Change from Baseline SF-36 scores at 6 months;Change from Baseline SF-36 scores at 1 year</time_frame>
    <description>mean improvement in SF-36 scores.Scale ranges 0-100 points, the higher score means the better efficacy.</description>
  </secondary_outcome>
  <number_of_groups>14</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>GERD</condition>
  <arm_group>
    <arm_group_label>Endoscopy-E(+)</arm_group_label>
    <description>Subjects with positive endoscopy finding:erosive esophagitis or Barrett esophagus.For subjects of this group, PPIs, Stretta,Laparoscopic Nissen fundoplication is considered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Endoscopy-E(-)</arm_group_label>
    <description>Subjects with negative endoscopy finding:NERD.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acid-A(+)</arm_group_label>
    <description>Subjects with DeMeester scores&gt;14.72.For subjects of this group, PPIs, Stretta,Laparoscopic Nissen fundoplication is considered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acid-A(-)</arm_group_label>
    <description>Subjects with DeMeester scores＜14.72</description>
  </arm_group>
  <arm_group>
    <arm_group_label>impedance-I（+）W/S</arm_group_label>
    <description>Subjects with total reflux number ＞ 80 in 24h pH-impedance monitoring. W means weakly acid reflux account for above 50% in total reflux number. G means gas reflux account for above 50% in total reflux number.For subjects of this group,probiotic agent is considered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>impedance-I（-）</arm_group_label>
    <description>Subjects with total reflux number ＜ 80 in 24h pH-impedance monitoring.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reflux-symptom association-S(+)</arm_group_label>
    <description>Subjects with positive reflux-symptom association.For subjects of this group, PPIs, Stretta, neuromodulators are considered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reflux-symptom association-S(-)</arm_group_label>
    <description>Subjects with negative reflux-symptom association</description>
  </arm_group>
  <arm_group>
    <arm_group_label>motility-M(+)</arm_group_label>
    <description>Subjects with motility disorders according to Chicago v3.0.For subjects of this group, prokinetic motility agents are considered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>motility-M(-)</arm_group_label>
    <description>Subjects without motility disorders according to Chicago v3.0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lower oesophageal sphincter-L(+)</arm_group_label>
    <description>Subjects with abnormal LES pressure or EGJ type III or hiatus hernia.For subjects of this group, Stretta,Laparoscopic Nissen fundoplication is considered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lower oesophageal sphincter-L(-)</arm_group_label>
    <description>Subjects with normal LES pressure and EGJ type I~II</description>
  </arm_group>
  <arm_group>
    <arm_group_label>psychology-P(+)</arm_group_label>
    <description>Subjects with normal psychology condition.For subjects of this group,neuromodulators are considered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>psychology-P(-)</arm_group_label>
    <description>Subjects with abnormal psychology condition</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stretta</intervention_name>
    <description>Stretta for Endoscopy-E(+),Acid-A(+),Reflux-symptom association-S(+) or lower oesophageal sphincter-L(+) group</description>
    <arm_group_label>Acid-A(+)</arm_group_label>
    <arm_group_label>Endoscopy-E(+)</arm_group_label>
    <arm_group_label>Reflux-symptom association-S(+)</arm_group_label>
    <arm_group_label>lower oesophageal sphincter-L(+)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laparoscopic Nissen fundoplication</intervention_name>
    <description>Laparoscopic Nissen fundoplication for E(+),A(+) or L(+) group</description>
    <arm_group_label>Acid-A(+)</arm_group_label>
    <arm_group_label>Endoscopy-E(+)</arm_group_label>
    <arm_group_label>lower oesophageal sphincter-L(+)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Probiotic Agent</intervention_name>
    <description>Probiotic Agent for I(+)G/W；Live Bacillus Licheniformis Cranules 0.5g bid； Bifidbacterium 0.63g bid</description>
    <arm_group_label>impedance-I（+）W/S</arm_group_label>
    <other_name>Live Bacillus Licheniformis Cranules</other_name>
    <other_name>Bifidbacterium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PPI</intervention_name>
    <description>PPIs for A(+),E(+)or S(+) patients: Nexium 20mg Qd/Bid;Lansoprazole 30mg Qd/Bid；omeprazole 10mg-30mg Qd-Bid;Rabeprazole 10mg Qd/Bid;Esomeprazole 20mg Qd/Bid;Pantoprazole 40mg Qd/Bid</description>
    <arm_group_label>Acid-A(+)</arm_group_label>
    <arm_group_label>Endoscopy-E(+)</arm_group_label>
    <arm_group_label>Reflux-symptom association-S(+)</arm_group_label>
    <other_name>omeprazole</other_name>
    <other_name>lansoprazole</other_name>
    <other_name>Rabeprazole</other_name>
    <other_name>Esomeprazole</other_name>
    <other_name>Pantoprazole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prokinetic Motility Agents</intervention_name>
    <description>Prokinetic Motility Agents for M(+) group; Mosapride 5mg Tid; Domperidone 10mg Tid</description>
    <arm_group_label>motility-M(+)</arm_group_label>
    <other_name>Mosapride</other_name>
    <other_name>Domperidone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neuromodulators</intervention_name>
    <description>Neuromodulators for P(+) or S(+);Flupentixol and Melitracen 1# bid;</description>
    <arm_group_label>Reflux-symptom association-S(+)</arm_group_label>
    <arm_group_label>psychology-P(+)</arm_group_label>
    <other_name>Flupentixol and Melitracen</other_name>
    <other_name>Citalopram</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult subjects with refractory gastroesophageal refulx symptoms.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or Female aged ≥18 years

          2. Subjects with refractory reflux symptoms to PPIs standard treatment as follows:

             2.1 Ongoing heartburn symptom with or without these GERD-related symptoms :
             Regurgitation, Non-cardiac chest pain, Epigastric pain, Belching, Bloating, Satiety,
             Sore throat, Cough, Laryngitis, Hoarseness, Nausea, Vomiting, Dysphagia, Odynophagia,
             Weight loss.

             2.2 Ongoing heartburn symptom with or without erosion ≥ grade A according to LA
             Classification.

          3. Decided to participate and signed on an informed consent form willingly.

        Exclusion Criteria:

          1. Existence of upper gastrointestinal bleeding or active gastroduodenal ulcer at
             screening.

          2. History of operation in esophagus, stomach or duodenum.

          3. Primary esophageal motility disease, Achalasia, Scleroderma, Esophageal/ pyloric
             stricture, Primary esophageal spasm, Barrett's esophagus ≥ 3 cm, Zollinger-Ellison
             syndrome.

          4. Infectious or inflammatory bowel disease, Severe malabsorption, Severe chronic heart
             failure, cardiovascular disease, renal failure, COPD, asthma, liver cirrhosis.

          5. History of cancer within 5 years, except completely recovered skin cancer ALT or AST ≥
             Upper limit of normal range X 3.

          6. Need antibiotics due to severe infection.

          7. Pregnant or breast-feeding women.

          8. Conversation impairment because of alcohol, drug addiction or mental illness, etc.

          9. Inability to record diary card

         10. In investigator's judgement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chuan Zhang, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Gatroenterology department,Beijing Tong Ren Hospital, Capital Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hao Zi Guo, MD</last_name>
    <phone>86+15801227696</phone>
    <email>zihaoguo@139.com</email>
  </overall_contact>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>June 21, 2018</study_first_submitted>
  <study_first_submitted_qc>July 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>February 2, 2019</last_update_submitted>
  <last_update_submitted_qc>February 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Capital Medical University</investigator_affiliation>
    <investigator_full_name>Guo Zihao</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Domperidone</mesh_term>
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Omeprazole</mesh_term>
    <mesh_term>Rabeprazole</mesh_term>
    <mesh_term>Pantoprazole</mesh_term>
    <mesh_term>Lansoprazole</mesh_term>
    <mesh_term>Mosapride</mesh_term>
    <mesh_term>Neurotransmitter Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data for all primary and secondary outcome measures will be made available.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data will be avialable within 1 months of study completion.</ipd_time_frame>
    <ipd_access_criteria>Data access requests will be reviewed by an external independant Review Panel. Requestors will be required to sign a Data Access Agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

